---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-030896"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:32:21.055335+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Madrigal Q1 Rezdiffra net sales $311.3M (+127% YoY); pipeline expanded with siRNA deal

## Summary
- Q1 2026 Rezdiffra net sales $311.3M, up 127% YoY from $137.3M; over 42,250 patients on therapy, 2.5x vs Q1 2025.
- Licensed ARO-PNPLA3 from Arrowhead; clinical-stage siRNA targeting PNPLA3 mutation in MASH (≈30% of F2/F3 patients).
- Net loss $94.4M ($3.25/share) vs $73.2M ($2.61) prior year; includes $54.3M one-time upfront BD expenses.
- Cash $817.9M at Mar 31 (down from $988.6M Dec 31); MGL-2086 Phase 1 on track for Q2 2026.
- Operating expenses $404.1M (incl $34M stock comp) vs $216.6M; SG&A up due to commercial investment.

## SEC filing metadata
- accession: 0001628280-26-030896
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/mdgl-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-030896
- JSON: https://secwatch.observer/filing/0001628280-26-030896.json
- Plain text: https://secwatch.observer/filing/0001628280-26-030896.txt

## Source-grounded claims
- claim_id: 9bee9b06118c4645c007065b80677d6ff039fc46
  claim: MADRIGAL PHARMACEUTICALS, INC. reported the quarter ended March 31, 2026 results: revenue $311.3 million, net income ($94.4 million) or ($3.25) per share (basic and diluted), EPS ($3.25).
  evidence_excerpt: (EX-99.1) --- Madrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.